Co-Diagnostics Inc Stock Price, News & Analysis

Co-Diagnostics (Nasdaq: CODX) announced the formation of a new artificial intelligence business unit, led by Chief Technology & AI Officer Christopher Thurston, to consolidate the company’s AI initiatives into the Co-Dx Primer Ai platform.

The company said the unit aims to accelerate development of proprietary AI-powered PCR diagnostics, support Co-Primers design and workflow orchestration, enable automated test interpretation, and integrate analytics via a HIPAA-compliant Co-Dx cloud. The release notes the Co-Dx PCR platform remains subject to FDA and other regulatory review and is not available for sale.

Co-Diagnostics (NASDAQ: CODX) will release its third quarter 2025 financial results on Thursday, November 13, 2025 after the market close.

The company will host a conference call and webcast the same day at 4:30 p.m. ET with Dwight Egan (CEO), Brian Brown (CFO), and Andrew Benson (Head of Investor Relations). The live webcast is available at ir.co-dx.com on the Events & Webcasts page, and the conference call numbers are 1-888-880-3330 (toll free) and 1-646-357-8766 (toll). A recorded replay will be posted on the company's website for those unable to attend live.

Co-Diagnostics (Nasdaq: CODX) will host a virtual fireside chat on November 5, 2025 at 11:00 am ET with CEO Dwight Egan to discuss the company’s growth initiatives and its recently announced definitive agreement with Arabian Eagle to form CoMira Diagnostics in Saudi Arabia.

The discussion will cover plans to advance regional deployment of the Co-Dx PCR platform across the Middle East. A live Q&A will follow; a recording will be posted on Co-Dx investor relations. Attendees may submit questions in advance to CODX@kcsa.com. Registration is available via the provided link. The Co-Dx PCR platform remains subject to regulatory review and is not currently available for sale.

Co-Diagnostics (Nasdaq: CODX) announced the closing of a registered direct offering of 12,727,272 shares of common stock (or pre-funded warrants) at $0.55 per share, generating gross proceeds of approximately $7.0 million before placement agent fees and offering expenses. The company said it intends to use the proceeds for working capital and general corporate purposes. Maxim Group acted as sole placement agent. The securities were offered under a shelf registration statement on Form S-3 declared effective by the SEC on April 6, 2023, and a prospectus supplement related to the Offering was filed with the SEC.

Co-Diagnostics (Nasdaq: CODX) announced a registered direct offering priced at-the-market to sell 12,727,272 shares of common stock (or pre-funded warrants) at $0.55 per share, with gross proceeds of approximately $7.0 million. The Company said proceeds will be used for working capital and general corporate purposes.

The Offering is expected to close on or about October 29, 2025, subject to customary closing conditions. Maxim Group is acting as sole placement agent. The securities are offered under a shelf registration statement on Form S-3 declared effective April 6, 2023, and a prospectus supplement will be filed with the SEC.

Co-Diagnostics (NASDAQ: CODX) signed a definitive joint venture agreement with Arabian Eagle to form CoMira Diagnostics in the Kingdom of Saudi Arabia to research, develop, manufacture, assemble, distribute, and commercialize Co-Dx technologies across KSA and 18 additional MENA countries. CoMira will pursue SFDA clearance to facilitate regional market entry and receive an exclusive license to manufacture and commercialize Co-Dx IP, including the upcoming Co-Dx PCR point-of-care platform. Infectious-disease tests slated for clinical evaluations before the end of 2025 include tuberculosis, an 8-type HPV multiplex, and a respiratory multiplex for influenza A/B, COVID-19, and RSV. The platform remains subject to regulatory review and is not yet available for sale.

Co-Diagnostics (NASDAQ: CODX) said its executive leadership team will attend and host a booth at Global Health Exhibition 2025 in Riyadh, KSA, on October 27–30, 2025. Attendees listed include CEO Dwight Egan, President Richard Abbott, Chief Commercialization and Strategy Officer Seth Egan, other department heads, and board member Eugene Durenard.

The company will showcase its Co-Dx infectious disease PCR products and the upcoming Co-Dx PCR point-of-care platform at Booth #H3.L17. The announcement follows a September 16 MOU exploring a joint venture to develop, manufacture, and sell Co-Dx IP across the Middle East and North Africa. The Co-Dx PCR platform is subject to regulatory review and not available for sale.

Co-Diagnostics (Nasdaq: CODX) announced development of a proprietary sample preparation instrument for its point-of-care Co-Dx PCR MTB test, designed for low-cost, user-friendly sample processing in resource-limited settings. The device supports sputum and a novel tongue swab method, uses single-button operation with no measuring tools, and includes a built-in safety feature to inactivate live organisms. Clinical evaluations in India for the MTB test are expected to begin before year-end 2025. Manufacturing is anticipated with Systronics under India’s "Make in India" initiative.

Co-Diagnostics (Nasdaq: CODX) announced it will participate in the 2025 Maxim Growth Summit on October 22-23 at The Hard Rock Hotel NYC. The company said it will hold one-on-one meetings with institutional investors and meet with senior Maxim analysts during the event.

The summit features keynote speakers Larry Kudlow and Christopher Ruddy, roundtable discussions across sectors including biotechnology and artificial intelligence, and sessions moderated by Maxim Research Analysts. For agenda details, attendees are directed to the Maxim Growth Summit website.